Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

NCT04517851 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis Transformation in Essential Thrombocythemia
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Primary Myelofibrosis

Interventions

BIOLOGICAL: Elotuzumab
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center